CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The recent correction in the tech sector might present some good opportunities to pick up some quality companies at far more attractive prices. Here are three I’m liking right now.
According to new research, the ASX has been the best share market in the world since 1900.
The CSL Limited (ASX:CSL) share price fell another 4% yesterday, meaning that shares have now dropped roughly 12% since it reported its half-year results. Time to buy?
The ASX 200 (ASX:XJO) is heading towards another negative open as the US tech sell-off continued overnight. Myer (ASX:MYR) and Xero (ASX:XRO) shares are in the news.
The S&P/ASX 200 (INDEXASX:XJO) finished flat on Thursday, but with growing dispersion in underlying company performance. Here’s a run-down of five big ASX reports.
The CSL Limited (ASX:CSL) share price has risen after the biotech giant announcing its FY21 half-year report.
I think it’s a pretty difficult investing environment right now, but there’s always a pocket of ASX shares that look interesting.
The S&P/ASX 200 (INDEXASX:XJO) is heading for a positive open on Wednesday after US markets pushed higher overnight. Credit Corp (ASX:CCP) and Vulcan (ASX:VUL) shares are in the news.
The S&P/ASX 200 (INDEXASX:XJO) is set to charge higher when the market opens on Tuesday. Worley (ASX:WOR) and Link (ASX:LNK) shares are in the news.
